Inhibrx Biosciences, Inc.
NASDAQInhibrx Biosciences heads into its May 15 earnings call sitting on a 70% one-month rally driven by clinical data — yet short sellers remain deeply embedded, setting up one of the more charged setups in small-cap biotech. The catalyst that lit the fuse came on April 22, when reports surfaced that large drugmakers were circling Inhibrx's cancer pipeline, with deal values cited above…
Snapshot as of 12 May 2026
Inhibrx Biosciences heads into its May 15 earnings call sitting on a 70% one-month rally driven by clinical data — yet short sellers remain deeply embedded, setting up one of the more charged setups in small-cap…
INBX has done something remarkable in the past month: it has more than doubled, rising 115% to $134.35 while carrying more than a quarter of its free float in short positions. That combination — a heavily shorted…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for INBX — free to start on ORTEX.
Sign up for free →Open INBX on ORTEX